PH23240A - Difluoronucleosides as antiviral agents - Google Patents

Difluoronucleosides as antiviral agents

Info

Publication number
PH23240A
PH23240A PH34549A PH34549A PH23240A PH 23240 A PH23240 A PH 23240A PH 34549 A PH34549 A PH 34549A PH 34549 A PH34549 A PH 34549A PH 23240 A PH23240 A PH 23240A
Authority
PH
Philippines
Prior art keywords
difluoronucleosides
antiviral agents
antiviral
agents
Prior art date
Application number
PH34549A
Other languages
English (en)
Inventor
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH23240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH23240A publication Critical patent/PH23240A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
PH34549A 1983-03-10 1986-12-03 Difluoronucleosides as antiviral agents PH23240A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor

Publications (1)

Publication Number Publication Date
PH23240A true PH23240A (en) 1989-06-06

Family

ID=23881409

Family Applications (2)

Application Number Title Priority Date Filing Date
PH34549A PH23240A (en) 1983-03-10 1986-12-03 Difluoronucleosides as antiviral agents
PH35983A PH23593A (en) 1983-03-10 1987-10-26 Difluoronucleosides as antiviral agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH35983A PH23593A (en) 1983-03-10 1987-10-26 Difluoronucleosides as antiviral agents

Country Status (36)

Country Link
US (5) US4526988A (enEXAMPLES)
EP (1) EP0122707B1 (enEXAMPLES)
JP (2) JPS59175498A (enEXAMPLES)
KR (1) KR860001283B1 (enEXAMPLES)
AR (1) AR243533A1 (enEXAMPLES)
AT (1) ATE29726T1 (enEXAMPLES)
AU (1) AU565856B2 (enEXAMPLES)
BG (1) BG40814A3 (enEXAMPLES)
CA (2) CA1218647A (enEXAMPLES)
CS (1) CS246075B2 (enEXAMPLES)
CY (1) CY1489A (enEXAMPLES)
DD (1) DD216468A5 (enEXAMPLES)
DE (2) DE19675003I2 (enEXAMPLES)
DK (2) DK162529C (enEXAMPLES)
ES (1) ES530364A0 (enEXAMPLES)
FI (1) FI77870C (enEXAMPLES)
GB (2) GB2136425B (enEXAMPLES)
GR (1) GR81845B (enEXAMPLES)
HK (1) HK44989A (enEXAMPLES)
HU (1) HU193893B (enEXAMPLES)
IE (1) IE57071B1 (enEXAMPLES)
IL (2) IL80463A (enEXAMPLES)
KE (1) KE3874A (enEXAMPLES)
LU (1) LU88791I2 (enEXAMPLES)
MX (1) MX9203246A (enEXAMPLES)
MY (1) MY102025A (enEXAMPLES)
NL (1) NL950018I2 (enEXAMPLES)
NZ (1) NZ207358A (enEXAMPLES)
PH (2) PH23240A (enEXAMPLES)
PL (1) PL142437B1 (enEXAMPLES)
PT (1) PT78181B (enEXAMPLES)
RO (1) RO89963A (enEXAMPLES)
SG (1) SG21889G (enEXAMPLES)
SU (1) SU1442076A3 (enEXAMPLES)
UA (1) UA5955A1 (enEXAMPLES)
ZA (1) ZA841605B (enEXAMPLES)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
EP0277599A3 (en) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Fluorine containing cyclopentane derivatives and processes for their production
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0688783B1 (en) 1987-08-28 2001-06-13 Eli Lilly And Company Method for preparing 2'-deoxy-2',2'-difluornucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
EP0364559B1 (en) * 1988-03-16 1995-09-20 The Scripps Research Institute Substituted adenine derivatives useful as therapeutic agents
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
CA2012129A1 (en) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recovery of difluoro sugar
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE69308400T2 (de) * 1992-06-22 1997-07-10 Lilly Co Eli Verfahren zur Stereoselektivanionglycosylierung
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
CA2098887C (en) * 1992-06-22 2003-10-28 Ta-Sen Chou Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2,2-difluoro-d-ribofuranosyl derivatives
US5256797A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5633367A (en) 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
AU1289697A (en) 1995-12-13 1997-07-03 Eli Lilly And Company Alpha, alpha-difluoro-beta-hydroxy thiol esters and their synthesis
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
AU6473098A (en) * 1997-03-24 1998-10-20 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
DE60126997T2 (de) * 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002365256A1 (en) * 2001-10-25 2003-07-30 Eli Lilly And Company Gemcitabine in the treatment of smallpox
AU2003235676A1 (en) * 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
AU2003217402A1 (en) * 2002-02-14 2003-09-04 Pharmasset Inc Modified fluorinated nucleoside analogues
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CA2525952A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
US20080026044A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
CA2734052A1 (en) * 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
WO2005044788A1 (ja) * 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
JP5235304B2 (ja) 2004-02-06 2013-07-10 スレショルド ファーマシューティカルズ インコーポレイティッド 抗癌療法
AU2005222384A1 (en) 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CN102199181B (zh) * 2004-07-21 2014-09-17 吉利德制药有限责任公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
CA2574954C (en) * 2004-07-29 2010-04-20 Hanmi Pharm. Co., Ltd. 1-.alpha.-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof
EP1812457A1 (en) * 2004-07-30 2007-08-01 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF ß-NUCLEOSIDES
CA2580457C (en) * 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
CA2586687A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
US7691827B2 (en) * 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
DE602005019626D1 (de) * 2005-03-04 2010-04-08 Fresenius Kabi Oncology Ltd Zwischenprodukt und verfahren zur herstellung von an beta-anomeren angereicherten 2'-desoxy,2',2'-difluor-d-ribufuranosylnukleosiden
US7485716B2 (en) * 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
BRPI0610950A2 (pt) * 2005-06-03 2010-08-03 Scinopharm Taiwan Ltd processo para produção de um sulfonato de 2-deoxi-2, 2-difluoro-d-ribofuranosil enriquecido de alfa anÈmero, e uso do mesmo para produção de um beta nocleosìdeo
WO2007011962A2 (en) 2005-07-18 2007-01-25 Bipar Sciences, Inc. Treatment of cancer
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007015257A2 (en) * 2005-08-04 2007-02-08 Hetero Drugs Limited A process for the preparation of gemcitabine using novel intermediates
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
EP1940859A1 (en) 2005-10-28 2008-07-09 Arch Pharmalabs Limited An improved process for preparation of gemcitabine hydrochloride
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
WO2007069838A1 (en) * 2005-12-14 2007-06-21 Dong-A Pharm.Co., Ltd. A manufacturing process of 2',2'-difluoronucleoside and intermediate
JP2009531284A (ja) * 2006-02-06 2009-09-03 ドクター レディズ ラボラトリーズ リミテッド ゲムシタビンの調製
CA2641719A1 (en) * 2006-02-07 2007-08-16 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2845866B1 (en) 2006-10-27 2017-05-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7714012B2 (en) * 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US7994310B2 (en) * 2007-03-23 2011-08-09 Dongwoo Syntech Co., Ltd. Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2009061894A1 (en) * 2007-11-06 2009-05-14 Pharmaessentia Corporation Novel synthesis of beta-nucleosides
AU2008324045B2 (en) 2007-11-09 2014-08-07 Affitech Research As Anti-VEGF antibody compositions and methods
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP2011503071A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
PT2252283T (pt) * 2008-01-11 2019-01-23 Reata Pharmaceuticals Inc Triterpenóides sintéticos e métodos de uso no tratamento de doença
KR101506062B1 (ko) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
NZ588709A (en) 2008-04-18 2012-11-30 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: triterpenoid oleanolic acid derivatives with saturation in the c-ring
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8350023B2 (en) * 2008-06-12 2013-01-08 ScnioPharm Taiwan, Ltd. Crystalline polymorphs of gemcitabine base
US8314137B2 (en) * 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
MX2011006892A (es) 2008-12-23 2011-07-20 Pharmasset Inc Sintesis de nucleosidos de purina.
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US8324180B2 (en) * 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
EP2416780B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
US20120129799A1 (en) 2009-07-31 2012-05-24 Astron Research Limited stable composition of ready-to-use gemcitabine injection
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CA2790176A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
PH12013500629A1 (en) 2010-09-22 2019-10-11 Alios Biopharma Inc Substituted nucleotide analogs
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
SI2694072T2 (sl) 2011-04-01 2024-10-30 Genentech, Inc. Kombinacija spojine, ki zavira AKT, in abiraterona za uporabo pri terapevtskem zdravljenju
US8765933B2 (en) 2011-04-07 2014-07-01 Pharmaessentia Corp. Asynthesis of β-nucleosides
CA2832449A1 (en) 2011-04-13 2012-10-18 Vinay GIRIJAVALLABHAN 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PH12013502141A1 (en) 2011-04-13 2014-01-06 Merck Sharp & Dohme 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2731434A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (enEXAMPLES) 2012-01-03 2018-03-31
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
SG11201406340QA (en) 2012-04-04 2014-11-27 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
CN107973856B (zh) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
PE20151318A1 (es) 2012-10-08 2015-10-03 Idenix Pharmaceuticals Inc Analogos de 2'-cloro nucleosido para infeccion por vhc
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
US20160324885A1 (en) * 2013-07-10 2016-11-10 Asteriapharma Gmbh Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
EP3024490A1 (en) * 2013-07-26 2016-06-01 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
SI3650014T1 (sl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
SG11201602614XA (en) 2013-10-29 2016-05-30 Otsuka Pharma Co Ltd Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
EP3164419B1 (en) 2014-06-26 2024-07-24 F. Hoffmann-La Roche AG Anti-brdu antibodies and methods of use
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
HK1245287A1 (zh) 2015-01-26 2018-08-24 The University Of Chicago IL13RAα2结合剂和其在癌症治疗中的用途
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
CN107295800A (zh) * 2015-02-25 2017-10-24 配体药物公司 吉西他滨衍生物
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2017060661A1 (en) * 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
LT3386998T (lt) 2015-12-11 2022-01-25 NuCana plc Fosfato darinių ir gemcitabino provaisto nuc-1031 diastereoselektyvi sintezė
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
CN110248673A (zh) 2016-11-21 2019-09-17 百祥制药公司 用于治疗胰腺癌的包括SapC-DOPS的联合疗法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1
BR112019022470A2 (pt) 2017-04-26 2020-05-12 I. Kalman Thomas Composto, composição, e, método para tratamento de um indivíduo com câncer.
JP2020519576A (ja) 2017-05-16 2020-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療
MA49849A (fr) 2017-08-07 2020-06-17 Amgen Inc Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
SG11202002114RA (en) 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4335496A3 (en) 2018-01-10 2025-08-27 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EA202091856A1 (ru) 2018-02-02 2020-12-07 Маверикс Онколоджи, Инк. Низкомолекулярные лекарственные коньюгаты гемцитабина монофосфата
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
US20220162299A1 (en) 2019-03-20 2022-05-26 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
KR20220002316A (ko) 2019-04-30 2022-01-06 인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스 Cdk 억제제와 조합된 rank 경로 억제제
WO2020263793A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
WO2025019361A1 (en) 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Scd1 inhibitors for treating hematolymphoid neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents

Also Published As

Publication number Publication date
GR81845B (enEXAMPLES) 1984-12-12
DE19675003I2 (de) 2003-05-22
US4526988A (en) 1985-07-02
EP0122707B1 (en) 1987-09-16
KE3874A (en) 1989-06-30
US4808614A (en) 1989-02-28
IL71143A0 (en) 1984-06-29
BG40814A3 (bg) 1987-02-16
DK162529B (da) 1991-11-11
KR860001283B1 (ko) 1986-09-05
EP0122707A1 (en) 1984-10-24
GB2172287A (en) 1986-09-17
FI840890A0 (fi) 1984-03-06
US5015743A (en) 1991-05-14
AU565856B2 (en) 1987-10-01
JPH0542438B2 (enEXAMPLES) 1993-06-28
AU2537484A (en) 1984-09-13
DK190590D0 (da) 1990-08-10
DK114484A (da) 1984-09-11
IL71143A (en) 1988-07-31
ES8602840A1 (es) 1985-12-01
PL246601A1 (en) 1985-08-13
DK170647B1 (da) 1995-11-20
NL950018I2 (nl) 1997-03-03
DK190590A (da) 1990-08-10
LU88791I2 (fr) 1996-11-05
KR840007883A (ko) 1984-12-11
IL80463A0 (en) 1987-01-30
MX9203246A (es) 1992-07-31
SG21889G (en) 1989-07-14
GB2136425A (en) 1984-09-19
UA5955A1 (uk) 1994-12-29
DK114484D0 (da) 1984-02-28
CA1218647A (en) 1987-03-03
US5118820A (en) 1992-06-02
MY102025A (en) 1992-02-29
IE840584L (en) 1984-09-10
JPH06102655B2 (ja) 1994-12-14
GB8405805D0 (en) 1984-04-11
RO89963A (ro) 1986-09-30
FI77870B (fi) 1989-01-31
HK44989A (en) 1989-06-09
GB2136425B (en) 1987-05-13
DD216468A5 (de) 1984-12-12
FI77870C (fi) 1989-05-10
CS246075B2 (en) 1986-10-16
ATE29726T1 (de) 1987-10-15
FI840890L (fi) 1984-09-11
IE57071B1 (en) 1992-04-22
HU193893B (en) 1987-12-28
ZA841605B (en) 1985-10-30
NL950018I1 (enEXAMPLES) 1995-11-01
ES530364A0 (es) 1985-12-01
JPS59175498A (ja) 1984-10-04
GB8610648D0 (en) 1986-06-04
PL142437B1 (en) 1987-10-31
JPH069602A (ja) 1994-01-18
PT78181B (en) 1986-08-05
IL80463A (en) 1988-07-31
AR243533A1 (es) 1993-08-31
GB2172287B (en) 1987-05-20
PT78181A (en) 1984-04-01
CY1489A (en) 1989-12-08
DK162529C (da) 1992-03-30
SU1442076A3 (ru) 1988-11-30
PH23593A (en) 1989-09-11
NZ207358A (en) 1987-03-06
US4692434A (en) 1987-09-08
CA1223869A (en) 1987-07-07
DE3466224D1 (en) 1987-10-22

Similar Documents

Publication Publication Date Title
PH23593A (en) Difluoronucleosides as antiviral agents
GB2150570B (en) Novel antiviral agents
GR80237B (en) Novel oxazolines as antiviral agents
PH19050A (en) Pest-combating agents
GB8320308D0 (en) Antiviral combinations
GB2119650B (en) Antiviral isothiosemicarbazones
ZA843152B (en) Antiviral agents
CS584184A2 (en) Zpusob vyroby derivatu benzamidinu s baktericidni ucinnosti
ZA837814B (en) Antiviral agent
DE3468322D1 (en) Antiviral agent
ZA844744B (en) Antiviral agents
CS709284A2 (en) Zpusob pripravy novych kondenzovanych derivatu as triazinu
DE3463443D1 (en) Hand piece
PH17379A (en) 4-arylaliphatic-isoxazoles useful as antiviral agents
GB8320309D0 (en) Antiviral compounds
GB8327824D0 (en) Mycostatic agents
GB8303406D0 (en) Smoke-flavouring agents
CS746585A2 (en) Zpusob pripravy novych kondezovanych derivatu as triazinu
CS669383A1 (en) Zpusob fermentacni vyroby thiaminasy i thiam
GB8330251D0 (en) Trestle
CS133783A1 (en) Zapojeni integracniho zesilovace s promennym prenosem
CS247783A1 (en) Zarizeni s plynule menitelnou excentricitou
CS169383A1 (en) Odvalovaci kladka s klenutym profilem odvalovaci plochy
CS265583A1 (en) Dvojchapadlo s posuvnym pohybom uchopovacich celusti
CS265283A1 (en) Stycnikova deska s prostrizenymi dvojicemi trnu